Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Doll

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
Journal of Medicinal Chemistry|January 22, 1998
Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compoundsF G Njoroge, B Vibulbhan, D F Rane, et al.
Journal of Medicinal Chemistry|June 23, 1999
Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationshipsC L Strickland, P C Weber, W T Windsor, et al.
Leukemia|November 7, 2025
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving conceptK S Kurz, A Zamo, C Drewes, et al.
Journal of Medicinal Chemistry|July 20, 1999
Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activitiesA G Taveras, J Deskus, J Chao, et al.
Cancer Research|November 11, 1998
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic miceM Liu, M S Bryant, J Chen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine CoreTao Yu, Jayaram R Tagat, Angela D Kerekes, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylationA K Mallams, F G Njoroge, R J Doll, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
Journal of Medicinal Chemistry|April 4, 1998
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazineA K Mallams, R R Rossman, R J Doll, et al.
Clinical Pharmacology and Therapeutics|December 9, 2024
Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled TrialTitia Q Ruijs, Catherine M K E de Cuba, Jules A A C Heuberger, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Journal of Medicinal Chemistry|January 22, 1998
Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compoundsF G Njoroge, B Vibulbhan, D F Rane, et al.
Journal of Medicinal Chemistry|June 23, 1999
Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationshipsC L Strickland, P C Weber, W T Windsor, et al.
Leukemia|November 7, 2025
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving conceptK S Kurz, A Zamo, C Drewes, et al.
Journal of Medicinal Chemistry|July 20, 1999
Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activitiesA G Taveras, J Deskus, J Chao, et al.
Cancer Research|November 11, 1998
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic miceM Liu, M S Bryant, J Chen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine CoreTao Yu, Jayaram R Tagat, Angela D Kerekes, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylationA K Mallams, F G Njoroge, R J Doll, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
Journal of Medicinal Chemistry|April 4, 1998
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazineA K Mallams, R R Rossman, R J Doll, et al.
Clinical Pharmacology and Therapeutics|December 9, 2024
Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled TrialTitia Q Ruijs, Catherine M K E de Cuba, Jules A A C Heuberger, et al.
Pageof 24